Oncolytics Biotech Inc T.ONC

AstraZeneca paid USD$ 5.5 Billion to co-market Enhertu

[Noteable]

March 2019 - AstraZeneca entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201) (Enhertu), a proprietary antibody-drug conjugate (ADC) a targeted medicine for cancer treatment.

Under the terms of the agreement, AstraZeneca paid Daiichi Sankyo an upfront payment of $1.35bn.

[Noteable]

August 23, 2022 - AstraZeneca is on the hunt for M&A deals amid the contraversy the company has seen over it's Covid 19 vaccine Vaxzevria business, involving production and delivery delays in Europe, and fears over rare blood clots. Now Astrazeneca is on the hunt for small and mid-sized acquisitions to bolster its business in cardiovascular disease and cancer, and the company is

[Noteable]

August 04, 2022 - AstraZeneca is working on ' off-the-self ' (allogeneic) CAR-T therapy with the intent of targeting solid tumors, according to Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit. "Targeting CAR-Ts in solid tumors is a widely held ambition among Big Pharma" ONCY has already demonstrated the curative effect of CAR-T therapy

[westcoast1000]

Noteable, Thanks for this helpful insight on ONCY and CAR-T potential. This is another exciting prospect for ONCY.

[Buckhenry]

[Noteable]

Just saying ....

[Noteable]

Enhertu® is made up of two cancer-fighting agents: an antibody attached to chemotherapy. Today Health Canada approved Enhertu for Her2-low metastatic breast cancer. Enhertu works by attacking cancer cells that have a Her2 protein on the cell surface and presents with side effects that are similar to those exhibited by chemotherapy, except to a lesser extent.  It is important to